Initial clinical experience with the Coherex FlatStent™ and FlatStent™ EF PFO closure system for in-tunnel PFO closure: Results of the Coherex-EU study

Sievert, Horst; Wunderlich, Nina; Reiffenstein, Isabel; Ruygrok, Peter; Grube, Eberhard; Büllesfeld, Lutz; Meier, Bernhard; Schofer, Joachim; Muller, David; Jones, Randall K; Gillam, Linda (2014). Initial clinical experience with the Coherex FlatStent™ and FlatStent™ EF PFO closure system for in-tunnel PFO closure: Results of the Coherex-EU study. Catheterization and cardiovascular interventions, 83(7), pp. 1135-1143. Wiley-Blackwell 10.1002/ccd.24565

[img] Text
ccd24565.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (234kB) | Request a copy

OBJECTIVE The Coherex-EU Study evaluated the safety and efficacy of PFO closure utilizing novel in-tunnel PFO closure devices. BACKGROUND Transcatheter closure of patent foramen ovale (PFO) followed the development of transcatheter closure devices designed to patch atrial septal defects (ASDs). The Coherex FlatStent™ and FlatStent™ EF devices were designed specifically to treat PFO anatomy. METHODS A total of 95 patients with a clinical indication for PFO closure were enrolled in a prospective, multicenter first in man study at six clinical sites. Thirty-six patients received the first-generation FlatStent study device, and 57 patients received the second-generation FlatStent EF study device, which was modified based on clinical experience during the first 38 cases. Two patients enrolled to receive the first generation did not receive a device. RESULTS At 6 months post-procedure, 45% (17/38) of the intention-to-treat (ITT) cohort receiving the first-generation FlatStent device had complete closure, 26% (10/38) had a trivial residual shunt, and 29% (11/38) had a moderate to large residual shunt. In the ITT cohort receiving the second-generation FlatStent EF device, 76% (43/57) had complete closure, 12% (7/57) had a trivial shunt, and 12% had a moderate to large shunt. Five major adverse events occurred, all without sequelae. CONCLUSION This initial study of the Coherex FlatStent/FlatStent EF PFO Closure System demonstrated the potential for in-tunnel PFO closure. The in-tunnel Coherex FlatStent EF may offer an alternative to septal repair devices for PFO closure in appropriately selected patients; however, further investigation will be necessary to establish the best use of this device.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Büllesfeld, Lutz and Meier, Bernhard


600 Technology > 610 Medicine & health








Daria Vogelsang

Date Deposited:

11 Jun 2014 14:31

Last Modified:

29 Oct 2015 10:45

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

patent foramen ovale, atrial septal defect, congenital heart disease in adults, fistula, shunts




Actions (login required)

Edit item Edit item
Provide Feedback